R. Scott Harris MD
Critical Care Medicine, Pleural Disease
Associate Professor, Medicine-Massachusetts General Hospital, Harvard Medical School
Join to view full profile
55 Fruit StCox 2Boston, MA 02114
Phone+1 617-726-1721
Fax+1 617-726-6878
Dr. Harris is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Massachusetts General Hospital/BIDMC/Harvard Medical SchoolFellowship, Pulmonary Disease and Critical Care Medicine, 1995 - 2000
Tufts Medical CenterResidency, Internal Medicine, 1991 - 1994
University of Massachusetts Medical SchoolClass of 1991
Certifications & Licensure
MA State Medical License 1993 - 2024
FL State Medical License 2014 - 2019
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014-2017
- CMS Meaningful Use Stage 2 Certification Longitudinal Medical Record, Partners Healthcare System, 2012, 2014-2017
- CMS Meaningful Use Stage 1 Certification Partners Longitudinal Medical Record, Partners Healthcare System, 2012, 2014-2017
Clinical Trials
Publications & Presentations
PubMed
- 6 citationsLong-term tezacaftor/ivacaftor safety and efficacy in people with cystic fibrosis and an F508del-CFTR mutation: 96-week, open-label extension of the EXTEND trial.Patrick A Flume, R Scott Harris, Hildegarde Paz-Diaz, Neil Ahluwalia, Mark Higgins
Journal of Cystic Fibrosis. 2023-05-01 - 3 citationsPerfusion imaging heterogeneity during NO inhalation distinguishes pulmonary arterial hypertension (PAH) from healthy subjects and has potential as an imaging biomarker.Tilo Winkler, Puja Kohli, Vanessa J Kelly, Ekaterina G Kehl, Alison S Witkin
Respiratory Research. 2022-12-01 - 12 citationsA Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children ≥ 6 years of age homozygous for F508del or het...Gregory S Sawicki, Mark Chilvers, John McNamara, Lutz Naehrlich, Clare Saunders
Journal of Cystic Fibrosis. 2022-07-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: